Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia
Open Access
- 15 April 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (s5) , S313-S320
- https://doi.org/10.1086/427446
Abstract
Despite recent improvements in outcomes of treatment for infection with hepatitis C virus (HCV), very few current injection drug users (IDUs) have access to treatment programs. We examined the natural history of and treatment knowledge about HCV infection and barriers and willingness to seek treatment for HCV infection. A convenience sample of current IDUs (n = 100) with self-reported HCV-positive status drawn from a primary health facility and methadone clinic in inner Sydney completed an interviewer-administered questionnaire. Participants had a reasonable knowledge of the natural history of HCV infection but poorer knowledge of treatment for HCV infection. Most believed that being a current IDU was an exclusion criterion for treatment. Despite this, 70%–80% of IDUs reported that they would consider treatment under current scenarios in Australia: requirement for liver biopsy, subcutaneous injections, common adverse effects, and 40% efficacy. Study participants at the methadone clinic had higher levels of consideration of treatment. These findings support the development of specific education programs regarding treatment for HCV infection for current IDUs.Keywords
This publication has 18 references indexed in Scilit:
- Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001International Journal of Epidemiology, 2003
- Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]PharmacoEconomics, 2003
- Prevention and treatment of hepatitis C in injection drug usersHepatology, 2002
- Epidemiology of hepatitis C virus infection in AustraliaJournal of Clinical Virology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis CGastroenterology, 2002
- Treating hepatitis C in methadone maintenance patients: an interim analysisDrug and Alcohol Dependence, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Treatment of Hepatitis C Infection in Injection Drug UsersHepatology, 2001
- Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatmentBMJ, 1999